2024-01-26 17:56:59 ET
Summary
- GSK's Q4 2023 and full-year 2023 earnings released later this month are expected to continue showing strength, especially with the successful launch of Arexvy, its respiratory disease vaccine.
- However, there are risks ahead too, as Zantac hearings are now underway and initial assessments of the company's earnings in 2024 are underwhelming.
- Still, much depends on the company's own outlook. In the meantime, its market multiples aren't high and it's dividend yield isn't bad either.
Since I last wrote an earnings preview on pharmaceuticals company GSK ( NYSE:GSK ) last October, its price is up by 11.8%, which was to be expected on good results and the settlement of its heartburn medication, Zantac, related cases in California. ...
Read the full article on Seeking Alpha
For further details see:
GSK: Robust Earnings Report Expected, 2024 Outlook Is Key